CN1180826C - Medicament for promoting exhaustion from anus and its preparation method - Google Patents
Medicament for promoting exhaustion from anus and its preparation method Download PDFInfo
- Publication number
- CN1180826C CN1180826C CNB02135443XA CN02135443A CN1180826C CN 1180826 C CN1180826 C CN 1180826C CN B02135443X A CNB02135443X A CN B02135443XA CN 02135443 A CN02135443 A CN 02135443A CN 1180826 C CN1180826 C CN 1180826C
- Authority
- CN
- China
- Prior art keywords
- radix
- ginger
- radix aucklandiae
- processed
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 210000000436 anus Anatomy 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title abstract description 49
- 230000001737 promoting effect Effects 0.000 title abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 241000234314 Zingiber Species 0.000 claims abstract description 23
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 23
- 235000008397 ginger Nutrition 0.000 claims abstract description 23
- 238000000605 extraction Methods 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000000654 additive Substances 0.000 claims abstract description 10
- 230000000996 additive effect Effects 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 6
- RLTYFLICIIZAKQ-UHFFFAOYSA-N Rhababerone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C=C(C)C(O)=C2 RLTYFLICIIZAKQ-UHFFFAOYSA-N 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 27
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 229940126701 oral medication Drugs 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 8
- 238000004821 distillation Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 229940126534 drug product Drugs 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000002893 slag Substances 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 16
- 230000003187 abdominal effect Effects 0.000 abstract description 14
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000218377 Magnoliaceae Species 0.000 abstract 2
- 235000002598 Inula helenium Nutrition 0.000 abstract 1
- 244000116484 Inula helenium Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 description 26
- 239000000243 solution Substances 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 6
- 239000012567 medical material Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 4
- 208000019790 abdominal distention Diseases 0.000 description 4
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 4
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229960005132 cisapride Drugs 0.000 description 3
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000011759 adducin Human genes 0.000 description 2
- 108010076723 adducin Proteins 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- -1 as decoction Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese medicine for promoting passage of gas of the anus. The Chinese medicine comprises components in weight portions as follows: 15 to 45 portions of ginger magnolias, 10 to 40 portions of aucklandia roots, 10 to 30 portions of stir-frying oranges and 5 to 15 portions of rhubarb. A preparing method is characterized in that the ginger magnolias and rhababerone are extracted and concentrated; elecampane water is distilled and extracted; the stir-frying oranges and aucklandia root residues are merged, extracted in an aqueous mode and concentrated; finally, a conventional medicinal additive agent is added to form medicinal products of different preparations according to clinic needs. The Chinese medicine can prompt a patient who receives an abdominal operation to discharge gas by the anus and treat enteroparalysis, and has the advantages of stable performance of product quality, less medication dose, short course of treatment, obvious effect and no toxic side effect. The Chinese medicine is particularly suitable for the patients who receiving the abdominal operation, and can make the patient eat in advance, strengthen the organic resistivity of the patients after the operation and prevent various complications after the operation. The preparing method is scientific and reasonable; medicinal material of different medicinal properties is processed in different modes, which ensures the extraction of active ingredients in the medicinal material and facilitates operation. Therefore, the Chinese medicine is suitable for industrial production.
Description
Technical field
The present invention relates to a kind of extract oral medicine and preparation method that promotes passage of gas by anus, belong to technical field of pharmaceuticals.
Background technology
Secular clinical experience shows that for the abdominal operation patient of surgery, the postoperative passage of gas by anus is common first indexs of paying attention to relevant with postoperative rehabilitation of doctors and patients.Therefore strengthening surgery abdominal operation postoperative passage of gas by anus is the rehabilitation that improves operation latter normal physiological function, promote the key of gastrointestinal motility, postoperative patient is taken food in advance, strengthen the body resistivity of postoperative patient, prevent the various complication of postoperative, reduce patient's misery and financial burden.
Report both at home and abroad at present, suffer from numerous organ diseases such as liver, gallbladder, spleen, kidney, pancreas, intestine and small intestine, bladder, need operator account for the over half of all surgery inpatients.And these surgical patients often since machinery wound, wasting QI-blood, mechanism of qi is obstructed, or because of insufficiency of vital energy and blood own, gas is capable not smooth, and gastrointestinal function is suppressed, the large intestine conduction function is not normal, and FU QI being obstructed causes the interior hydrops of enteric cavity to increase, not aerofluxus of anus, vomiting, even complication such as dyspnea, early stage enteroparalysis often appear with the abdominal distention discomfort, cause patient's postoperative misery, severe patient can form intestinal obstruction.And conventional treatment method is clinically just taked simple postoperative gastrointestinal decompression, fasting or with " neostigmine " injection or place the anal canal height and ooze low pressure enema, defeated 10% potassium chloride etc. that drips of vein, it is long that these methods have the time, and drawback patients such as complex operation are difficult for accepting.The medicine of present clinical use has " Decoction of Four-Drug Juice " and cisapride, and Chinese medicine " Decoction of Four-Drug Juice " is made up of the Radix Aucklandiae, Fructus Aurantii, the Radix Linderae, Semen Arecae four Chinese medicine, is Song dynasty masterpiece recipes for Saving Lives.Mainly be long-pending to help digestion, be mainly used in children's's breast food and stagnate, dyspepsia type gastrointestinal dysfunction diseases such as abdominal distention, stomachache, anorexia poor appetite, constipation, middle-aged and elderly people distension and fullness in the abdomen, stomachache, constipation, only adversary's postoperative abdominal distention has the effect of alleviation, can not reach the final purpose of treatment and prevention enteroparalysis, and complicated process of preparation, the cost height, the course of treatment is long; The Western medicine cisapride is the gastric motility promoting drug, but toxic and side effects is big, is unfavorable for the rehabilitation of postoperative patient.
Summary of the invention
Technical problem to be solved by this invention is: provide a kind of patient of making to shift to an earlier date passage of gas by anus, can treat the aerofluxus oral drugs of abdominal postoperative enteroparalysis, its capability and performance is stable, and dosage is few, short treating period, and instant effect, without any side effects; The present invention provides the preparation method easy to implement that is suitable for suitability for industrialized production simultaneously.
Aerofluxus oral drugs of the present invention, make by following materials of weight proportions:
15～45 parts of Cortex Magnoliae Officinalis(processed with ginger), 10～40 parts of the Radix Aucklandiae, 10～30 parts of Fructus Aurantii Immaturus (parched with bran), 5～15 parts of Radix Et Rhizoma Rhei.
Wherein optimum proportion consists of:
30 parts of Cortex Magnoliae Officinalis(processed with ginger), 20 parts of the Radix Aucklandiae, 20 parts of Fructus Aurantii Immaturus (parched with bran), 10 parts of Radix Et Rhizoma Rhei.
It is under the enlightenment of Eastern Han Dynasty's Zhang Zhongjing " Medical Treasures of the Golden Chamber " Cortex Magnoliae Officinalis three thing soup that the present invention forms, and repeatedly practises through clinical, adds the Radix Aucklandiae of circulation of qi promoting intestinal stasis relieving on the basis of Cortex Magnoliae Officinalis three thing soup again, is intended to strengthen its circulation of qi promoting effect.With the relieving distension by promoting circulation of QI is major function, and it is caused specially to control abdominal postoperative, Qi-stagnation type enteroparalysis in period disease.Making postoperative patient shift to an earlier date passage of gas by anus, feed early, is that first specially controls the pure Chinese medicinal preparation of abdominal postoperative enteroparalysis at present.
Mostly the early stage enteroparalysis of postoperative is that patient shows as abdominal distention and pain more owing to the gastrointestinal motility miopragia, and aerofluxus is late excessively, constipation due to dry stool etc.From the viewpoint of Chinese medicine, gastrointestinal function is " excretion without storage ", " moving and not quiet ", " merit is not being kept walking ", thus we to have selected relieving distension by promoting circulation of QI be main, the purging FU-organs removing the relative excess is that the Chinese medicine of assisting is made medicine of the present invention.Cortex Magnoliae Officinalis has the effect of warming middle-JIAO, the therapeutic method to keep the adverse QI flowing downwards in the side, is used for breast abdomen feeling of fullness distending pain, is the monarch drug in the side, promoting the circulation of QI to alleviate the stagnation in middle-JIAO, and it is full to change backwater; The Radix Aucklandiae is the circulation of qi promoting intestinal stasis relieving, and the key medicine of warming middle-JIAO for easing the stomach is controlled the invasion by pathogenic cold stagnation of QI, distension and fullness of the chest and abdomen, and this is a ministerial drug in side's neutrality, the power of Reinforcement Group pharmacology gas, two medicines are harmonious, and make mechanism of qi unobstructed, eliminate the disease of distension pain; Fructus Aurantii Immaturus energy removing mass intestinal stasis relieving rushes down the diffusing painful abdominal mass of expectorant, controls distension and fullness of the chest and abdomen, is adjuvant drug.Join Radix Et Rhizoma Rhei, Cortex Magnoliae Officinalis etc. and control constipation with heat retention, stomachache forceful pulse etc.; The Radix Et Rhizoma Rhei poison that can purge heat, removing mass stagnates, and clots absorbing blood is controlled the excess-heat constipation, the food stagnation feeling of fullness, abdominal mass such as gathers at disease, messenger drug in the genus side.The merit of the circulation of qi promoting by Cortex Magnoliae Officinalis, the Radix Aucklandiae, Fructus Aurantii Immaturus three flavor medicines helps altogether rushes down down reality, cleanses the intestines and stomach excess-heat, and Radix Et Rhizoma Rhei is real to be the medicine of using corrigent, make its we warm and not dry, regulate the flow of vital energy and impairment of YIN not, all medicine compatibilities gather special effect altogether, reach the alleviating distention in middle-JIAO relieving distension by promoting circulation of QI, the effect of the removing stagnancy of pathogens for obstruction of FU-organ, cure mainly the early stage enteroparalysis of abdominal postoperative, reach the patients after surgery anus and shift to an earlier date deflated purpose, postoperative patient is taken food early, strengthen the human body resistivity, prevent the various complication of postoperative.
Industrialized preparing process easy to implement is as follows:
With Cortex Magnoliae Officinalis(processed with ginger), Radix Et Rhizoma Rhei alcohol extraction, concentrated wherein; Radix Aucklandiae water distillation and extraction; Fructus Aurantii Immaturus (parched with bran) and Radix Aucklandiae slag merge after water is carried, precipitate with ethanol makes medicinal liquid contain the alcohol amount to reach 70%, concentrate, will extract medicine part mix drug products.In actual production, need add conventional pharmaceutic adjuvant or be called the drug products that additive is made different dosage form according to clinical needs.
In implementation process:
It is alkalescence that Cortex Magnoliae Officinalis(processed with ginger), rhababerone extract are preferably regulated pH value with medicinal basic, and medicinal basic has a lot, as sodium hydroxide, sodium carbonate, sodium bicarbonate etc., is 7～8 as regulating pH value with 20% sodium hydroxide solution.
It is better for the re-distilled liquid through second distillation that the Radix Aucklandiae is soaked the distillate of obtaining, the active constituent content height of the Radix Aucklandiae in the re-distilled liquid of acquisition.
The boil water extract of the Fructus Aurantii Immaturus (parched with bran) and the Radix Aucklandiae is convenient to despumation after handling through precipitate with ethanol, is beneficial to the extraction of effective ingredient and concentrates.Each extracting solution through concentration, is for further processing again, and technological effect is better.
For the pharmacy routine operation, as alcohol extraction, the water of Chinese crude drug carry, precipitate with ethanol, concentrate, operating procedures such as distillation, immersion, decocting, and each operating parameter operates routinely to adjust and determines to get final product, and is not repeated at this.
The aerofluxus oral drugs of component of the present invention can be made clinical suitable oral Pharmaceutical dosage forms, as decoction, mixture, electuary etc.Can add corresponding additive during preparation, as suitable adjuvant, correctives, aromatic, coloring agent etc., the addition of additive is operated routinely.
Decoction is meant with Chinese crude drug and decocts with water that the liquid dosage form that the extracting juice that removes slag is made also is called " decoct ".With medical material water or other solvents, adopt proper method to extract, through concentrating the liquid preparation of making for oral administration, be called herb mixture.
Electuary means the granular formulations that medicinal substances extract and adjuvant that suits or medical material fine powder are made.The method for making of electuary generally can be divided into extraction, concentrates, granulates, dry, screening and packaging and other steps.
The preparation of aerofluxus mixture: with alcohol extraction, the concentrated solution of Cortex Magnoliae Officinalis(processed with ginger) and Radix Et Rhizoma Rhei, the water of Radix Aucklandiae water distillate and Fructus Aurantii Immaturus (parched with bran) and the Radix Aucklandiae is carried, precipitate with ethanol, concentrated solution, mixed aerofluxus mixture.The additive that adds has stabilizing agent: glycerol, antiseptic: ethyl hydroxybenzoate, methyl hydroxybenzoate etc.; Correctives: steviosin etc., concrete operations are with the final concentrated solution of Cortex Magnoliae Officinalis(processed with ginger) and Radix Et Rhizoma Rhei and glycerol mixing, add ethyl hydroxybenzoate and steviosin, stir down slowly to join in the Radix Aucklandiae water distillate, and then with the final concentrated solution mixing of the Fructus Aurantii Immaturus (parched with bran) and the Radix Aucklandiae, filter, packing gets finished product.
The preparation of aerofluxus electuary: with the water of alcohol extraction, concentrated solution and the Fructus Aurantii Immaturus (parched with bran) of Cortex Magnoliae Officinalis(processed with ginger) and Radix Et Rhizoma Rhei and the Radix Aucklandiae carry, precipitate with ethanol, concentrated solution mixing granulation, add Radix Aucklandiae water distillate after the dried, mix soak into after, make the aerofluxus electuary.The additive that adds is: sucrose, steviosin etc.Concrete operations are that sucrose, steviosin powder are joined in the concentrated solution mixed liquor of the concentrated solution of Cortex Magnoliae Officinalis(processed with ginger) and Radix Et Rhizoma Rhei and the Fructus Aurantii Immaturus (parched with bran) and the Radix Aucklandiae, fully mix, the preparation granule, add Radix Aucklandiae water distillate behind the particle drying, place soak into product.
The product experiment is as follows:
Pharmacodynamics test: be study subject with mice after normal mouse and the typhlectomy respectively, observe that high, medium and low dosage of aerofluxus mixture of the present invention (10g/kg, 5g/kg, 1g/kg) and Decoction of Four-Drug Juice (4ml/kg), cisapride (5mg/kg) advance the mouse small intestine carbon powder and the influence of carbon powder efflux time.The result shows: aerofluxus mixture height, middle dosage group and cisapride group all have obvious facilitation (P＜0.05 or P＜0.01) to normal mouse and postoperative mouse small intestine carbon powder propelling rate and carbon powder efflux time; Aerofluxus mixture small dose group, Decoction of Four-Drug Juice group also have obvious facilitation (P＜0.05 or P＜0.01) to postoperative mouse small intestine carbon powder propelling rate, carbon powder efflux time and normal mouse carbon powder efflux time, but effect does not have significance (P＞0.05) to small intestine movement of mice carbon powder propelling rate.With cisapride group and Decoction of Four-Drug Juice group relatively, Chinese medicine aerofluxus mixture high dose group effect more obvious (P＜0.05 or P＜0.01), and in, small dose group difference do not have significance (P＞0.05).Show that Chinese medicine aerofluxus mixture has better action to enteroparalysis after promoting the normal mouse enterokinesia, recovering the mice typhlectomy.
Preliminarily stabilised test: with reference to the requirement under " provisions for new drugs approval-relevant Chinese medicine revision and supplementary provisions partly " Chinese medicine stability test item, Chinese medicine aerofluxus mixture is packed (glass bottle in clinical trial usefulness, sealing) under the condition, adopt the reserved sample observing method, three batch samples were placed three months in shady and cool dry place under room temperature (25-35 ℃), regulation according to Chinese medicine aerofluxus mixture quality standard (draft) and Ministry of Public Health medicine sanitary standard promulgated by the ministries or commissions of the Central Government, to its character, differentiate, check, assay, projects such as health examination detect, through the preliminarily stabilised examination, show that the quality of this product is more stable.
Acute toxicity test: divide in the mice 24 hours to give Chinese medicine aerofluxus mixture concentrated solution (3.67g/ml) 3 times, each 0.5ml, maximum tolerance capacity is 75.11ml/kg, tolerance crude drug amount is 275.65g/kg, calculate by kg body weight, be equivalent to more than 25 times of Coming-of-Age Day dosage.Little, the safety of the oral said preparation acute toxicity of mice is described, clinical practice can be provided.
Long term toxicity test: with the healthy SD rat is study subject, and 7 days animal ordinary circumstances, body weight, hemogram, blood parameters, organ coefficient and 10 kinds of main organs histopathology change after the observation large and small dosage of aerofluxus mixture (60g/kg, 6g/kg) successive administration 15 days and the drug withdrawal.The result shows: compare with the normal control group, the large and small dosage group of aerofluxus mixture of the present invention successive administration changed basically identical at animal ordinary circumstance, body weight gain, hemogram, serum darling renal function index, blood glucose, blood fat, serum ion, organ coefficient and 10 kinds of aspects such as main organs histopathology after 15 days, and difference does not have significance (P＞0.05).Show that Chinese medicine aerofluxus mixture is little to the rat long term toxicity, safety good, clinical practice can be provided.
Oral drugs of the present invention have successively carried out observation on Clinical Application to 220 routine abdominal operation patients, gastrointestinal procedures 134 examples wherein, and abdominal part hepatobiliary surgery 86 examples are divided into two groups by randomly assigne, i.e. and 118 examples are organized in treatment, matched group 102 routine conventional methods.Method of administration began to take 50ml in preceding 12 hours for operation, and perform the operation began to take medicine in back 6 hours; One twice-daily, each 50ml, the conventional gastrointestinal decompression of matched group is handled.
Therapeutic outcome and conventional treatment relatively, on average 19 hours in advance recovery time of treatment group borborygmus, passage of gas by anus on average 40 hours in advance, clinical total effective rate be 96% and the curative effect of blank group relatively, have utmost point significant difference (P＜0.01), see Table 1.And find no any toxicity, confirm that this preparation shifts to an earlier date passage of gas by anus to postoperative definite curative effect is arranged, and safety non-toxic, clinical use can be provided fully.
Table 1,220 routine abdominal postoperative borborygmus times and passage of gas by anus time (X ± a)
| Group | Case (n) | The borborygmus time (h) | Evacuation time (h) |
| The treatment group | 118 | 18.6±13.6 | 20.8±14.2 |
| Matched group (not medication) | 102 | 37.3±17.0 | 60.8±20.2 |
The brand-new compatibility of oral drugs of the present invention is formed high quality materials, batching science, can make the abdominal operation patient shift to an earlier date passage of gas by anus, can treat the abdominal postoperative enteroparalysis, and capability and performance is stable, dosage is few, short treating period, instant effect, without any side effects, suitable clinical especially abdominal operation patient uses, and postoperative patient is taken food in advance, strengthens the body resistivity of postoperative patient, prevent the various complication of postoperative, reduce patient's misery and financial burden.The preparation method of oral drugs of the present invention is scientific and reasonable, and different medicine parts are selected for use different processing methods, has both guaranteed the extraction of the effective ingredient in medicine part, is convenient to operation again, is suitable for suitability for industrialized production.
The specific embodiment
The invention will be further described below in conjunction with embodiment.
Embodiment 1
The ingredients by weight of aerofluxus oral drugs of the present invention consists of:
Cortex Magnoliae Officinalis(processed with ginger) 300 grams, the Radix Aucklandiae 200 grams, Fructus Aurantii Immaturus (parched with bran) 200 grams, Radix Et Rhizoma Rhei 100 grams.
The above aerofluxus mixture preparation method of Zu Chenging:
Cortex Magnoliae Officinalis(processed with ginger), Radix Et Rhizoma Rhei powder are broken into coarse powder, add 65% soak with ethanol more than 12 hours, the reflux, extract, secondary, alcohol adding amount is respectively 10 times, 8 times amounts of medical material, extraction time was respectively 2.5,2.0 hours, collected alcohol extract twice, transferred pH7.5 with 20%Na0H solution, be concentrated into about 1.10 (80 ℃ of heat are surveyed) of relative density, standby.Get the Radix Aucklandiae, add 8 times of water gagings, soaked 1.5 hours, the distillate of amount of water 60% is collected in distillation, and redistillation is once collected half re-distilled liquid of distillate amount for the first time, and is standby.Get Fructus Aurantii Immaturus (parched with bran), merge, soaked 1.5 hours with Radix Aucklandiae medicinal residues, boil the extraction secondary, amount of water is respectively 10 times, 8 times of medical material, and extraction time was respectively 2.5,2.0 hours, collect the water extract, be concentrated into relative density about 1.06 (80 ℃ of heat are surveyed), under agitation slowly add 95% ethanol and make medicinal liquid contain the alcohol amount to reach 70%, left standstill 24 hours, precipitate with ethanol, filter, be concentrated into about 1.27 (80 ℃ of heat are surveyed) of relative density, standby.Get Cortex Magnoliae Officinalis(processed with ginger), rhababerone extraction, concentrated solution and 150ml glycerol mixing, add 0.1% ethyl hydroxybenzoate and 1.0% steviosin, stir down and slowly joins in the Radix Aucklandiae re-distilled liquid, carry with the Purified Water of Fructus Aurantii Immaturus (parched with bran), the Radix Aucklandiae then, concentrated solution mixes.Its mixed liquor adds water to 120000ml, stirs evenly, and is distributed into finished product.
The above aerofluxus electuary preparation method of Zu Chenging:
Cortex Magnoliae Officinalis(processed with ginger), Radix Et Rhizoma Rhei powder are broken into coarse powder, add 65% soak with ethanol more than 12 hours, the reflux, extract, secondary, alcohol adding amount is respectively 10 times, 8 times amounts of medical material, extraction time was respectively 2.5,2.0 hours, collected alcohol extract twice, transferred pH7.5 with 20%NaOH solution, be concentrated into about 1.10 (80 ℃ of heat are surveyed) of relative density, standby.Get the Radix Aucklandiae, add 8 times of water gagings, soaked 1.5 hours, the distillate of amount of water 60% is collected in distillation, and redistillation is once collected half re-distilled liquid of distillate amount for the first time, and is standby.Get Fructus Aurantii Immaturus (parched with bran), merge, soaked 1.5 hours with Radix Aucklandiae medicinal residues, boil the extraction secondary, amount of water is respectively 10 times, 8 times of medical material, and extraction time was respectively 2.5,2.0 hours, collect the water extract, be concentrated into relative density about 1.06 (80 ℃ of heat are surveyed), under agitation slowly add 95% ethanol and make medicinal liquid contain the alcohol amount to reach 70%, left standstill 24 hours, precipitate with ethanol, filter, be concentrated into about 1.27 (80 ℃ of heat are surveyed) of relative density, standby.In addition 80 mesh sieves are pulverized, crossed to the additive sucrose of amount of calculation, join in the extraction concentrated solution of above-mentioned Cortex Magnoliae Officinalis(processed with ginger), Radix Et Rhizoma Rhei and Fructus Aurantii Immaturus (parched with bran), the Radix Aucklandiae, fully mix, make granule, under 65 ℃ of conditions dry about 3 hours then, add Radix Aucklandiae re-distilled liquid again and carry out always mixing 2-5 minute, and place to soak into and treated that quality inspection promptly was distributed into bag after qualified in about 4 hours.
Embodiment 2
Cortex Magnoliae Officinalis(processed with ginger) 300g, Radix Aucklandiae 200g, Fructus Aurantii Immaturus (parched with bran) 200g, Radix Et Rhizoma Rhei 100g add up to 800g.
Preparation aerofluxus mixture:
The 32kg (800g * 40) that feeds intake in batches, dosing total amount 40000ml, packing specification: 100ml/ bottle.
Additive: glycerol 6000ml, ethyl hydroxybenzoate 40g, steviosin 400g.
Embodiment 3～8 ingredients by weight are formed (g * 80) situation and are seen Table 2.Each additive operating position ratio is with embodiment 1.
Table 2, embodiment ingredients by weight are formed table
| Medicine part is formed | Cortex Magnoliae Officinalis(processed with ginger) | The Radix Aucklandiae | Fructus Aurantii Immaturus (parched with bran) | Radix Et Rhizoma Rhei | Dosage form |
| Embodiment 3 | 160 | 300 | 300 | 60 | Mixture |
| Embodiment 4 | 400 | 250 | 250 | 110 | Mixture |
| Embodiment 5 | 250 | 250 | 200 | 100 | Mixture |
| Embodiment 6 | 200 | 300 | 150 | 50 | Mixture |
| Embodiment 7 | 420 | 200 | 220 | 90 | Electuary |
| Embodiment 8 | 350 | 300 | 250 | 120 | Electuary |
Claims (7)
1, a kind of oral drugs that promote passage of gas by anus is characterized in that being made by following materials of weight proportions:
15～45 parts of Cortex Magnoliae Officinalis(processed with ginger), 10～40 parts of the Radix Aucklandiae, 10～30 parts of Fructus Aurantii Immaturus (parched with bran), 5～15 parts of Radix Et Rhizoma Rhei.
2, aerofluxus oral drugs according to claim 1 is characterized in that being made by following materials of weight proportions:
30 parts of Cortex Magnoliae Officinalis(processed with ginger), 20 parts of the Radix Aucklandiae, 20 parts of Fructus Aurantii Immaturus (parched with bran), 10 parts of Radix Et Rhizoma Rhei.
3,, it is characterized in that Cortex Magnoliae Officinalis(processed with ginger), Radix Et Rhizoma Rhei alcohol extraction, concentrate according to the preparation method of the described aerofluxus oral drugs of claim 1; Radix Aucklandiae water distillation and extraction; Fructus Aurantii Immaturus (parched with bran) and Radix Aucklandiae slag merge after water is carried, precipitate with ethanol makes medicinal liquid contain the alcohol amount to reach 70%, concentrate, add the drug products that medical additive is made different dosage form at last.
4, preparation method according to claim 3 is characterized in that it is 7～8 that Cortex Magnoliae Officinalis(processed with ginger), rhababerone extract are regulated pH value with medicinal basic.
5, preparation method according to claim 3 is characterized in that it is the re-distilled liquid of process second distillation that the Radix Aucklandiae is soaked the distillate of obtaining.
6,, it is characterized in that the water of Radix Aucklandiae water distillate and Fructus Aurantii Immaturus (parched with bran) and the Radix Aucklandiae is carried with alcohol extraction, the concentrated solution of Cortex Magnoliae Officinalis(processed with ginger) and Radix Et Rhizoma Rhei, concentrated solution, the mixed aerofluxus mixture that gets according to claim 3,4 or 5 described preparation methoies.
7, according to claim 3,4 or 5 described preparation methoies, it is characterized in that with the water of alcohol extraction, concentrated solution and the Fructus Aurantii Immaturus (parched with bran) of Cortex Magnoliae Officinalis(processed with ginger) and Radix Et Rhizoma Rhei and the Radix Aucklandiae carry, the concentrated solution mixing granulation, add Radix Aucklandiae water distillate after the dried, mixing makes the aerofluxus electuary after soaking into.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB02135443XA CN1180826C (en) | 2002-08-29 | 2002-08-29 | Medicament for promoting exhaustion from anus and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB02135443XA CN1180826C (en) | 2002-08-29 | 2002-08-29 | Medicament for promoting exhaustion from anus and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1415339A CN1415339A (en) | 2003-05-07 |
| CN1180826C true CN1180826C (en) | 2004-12-22 |
Family
ID=4748202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB02135443XA Expired - Lifetime CN1180826C (en) | 2002-08-29 | 2002-08-29 | Medicament for promoting exhaustion from anus and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1180826C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107569561A (en) * | 2017-10-31 | 2018-01-12 | 瑞阳制药有限公司 | The masking methods of Houpo Paiqi Mixture, Houpo Paiqi Mixture and preparation method thereof |
-
2002
- 2002-08-29 CN CNB02135443XA patent/CN1180826C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1415339A (en) | 2003-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1317026C (en) | Traditional Chinese medicine prepn. for treating lithiasis and its prepn. method | |
| CN101129994A (en) | Traditional Chinese medicine composition for treating icterus | |
| CN101590168B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101590184B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101590167B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101590169B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN107115493A (en) | It is a kind of to treat Chinese medicine composition of fracture and its production and use | |
| CN1180826C (en) | Medicament for promoting exhaustion from anus and its preparation method | |
| CN101890062A (en) | Use of nardostachys chinensis batal and extract thereof in preparation of medicaments for treating gastric ulcer | |
| CN101843804A (en) | Chinese medicament for treating benign prostatic hyperplasiabrain | |
| CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN101590166B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN103444957A (en) | Health tea electuary for treating constipation based on food therapy | |
| JPH04243834A (en) | Pharmaceutical composition | |
| CN1927282A (en) | Preparation for treating arthritis and preparation method thereof | |
| CN1480161A (en) | Preparation of Chinese herbal medicine for treating lithiasis as well as its preparing method | |
| CN104800487B (en) | It is a kind of to be used to treat traditional Chinese medicinal ointment of chronic constipation and preparation method thereof | |
| CN1143514A (en) | Medicament and medicinal liquor for treating gastropathy and preparation | |
| CN1238013C (en) | Myocarditis treating Chinese medicine prepn | |
| CN101376017A (en) | Chinese medicine for treating constipation and preparation method thereof | |
| CN1733197A (en) | Medicine for curing chronic prostatitis and process for preparing the same | |
| CN105497459A (en) | Traditional Chinese medicine preparation for treating woman leukorrheal diseases as well as preparation method and application of traditional Chinese medicine preparation | |
| CN101518591B (en) | Traditional Chinese medicine for treating diabetic constipation | |
| CN104208511A (en) | Yao medicine composition capable of strengthening stomach and removing dampness and preparation method thereof | |
| CN1258373C (en) | Medicine for treating lumbosacral pain and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: RUIYANG PHARMACY CO., LTD. Free format text: FORMER NAME OR ADDRESS: SHANGDONG RUIYANG PHARMACEUTICAL CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: No. 6 Erlang mountain road, Yiyuan County, Zibo, Shandong Patentee after: REYOUNG PHARMACEUTICAL Co.,Ltd. Address before: No. 6 Erlang mountain road, Yiyuan County, Zibo, Shandong Patentee before: SHANDONG REYOUNG PHARMACEUTICA |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicament for promoting exhaustion from anus and its preparation method Effective date of registration: 20161027 Granted publication date: 20041222 Pledgee: Agricultural Bank of China Limited by Share Ltd. Yiyuan county subbranch Pledgor: REYOUNG PHARMACEUTICAL Co.,Ltd. Registration number: 2016990000912 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 256100 No. 6 Erlang Road, Yiyuan County, Zibo, Shandong Patentee after: Ruiyang Pharmaceutical Co.,Ltd. Address before: 256100 No. 6 Erlang Road, Yiyuan County, Zibo, Shandong Patentee before: REYOUNG PHARMACEUTICAL Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201228 Granted publication date: 20041222 Pledgee: Agricultural Bank of China Limited by Share Ltd. Yiyuan county subbranch Pledgor: REYOUNG PHARMACEUTICAL Co.,Ltd. Registration number: 2016990000912 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 20041222 |
|
| CX01 | Expiry of patent term |